Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2013, Article ID 575936, 6 pages
http://dx.doi.org/10.1155/2013/575936
Review Article

Postmenopausal Osteoporosis: The Role of Immune System Cells

1Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, 70124 Bari, Italy
2Institute for Biomedical Technologies, National Research Council, 70126 Bari, Italy

Received 3 April 2013; Accepted 10 May 2013

Academic Editor: Giacomina Brunetti

Copyright © 2013 Maria Felicia Faienza et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. Clowes, B. L. Riggs, and S. Khosla, “The role of the immune system in the pathophysiology of osteoporosis,” Immunological Reviews, vol. 208, pp. 207–227, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Ginaldi, M. C. Di Benedetto, and M. De Martinis, “Osteoporosis, inflammation and ageing,” Immunity and Ageing, vol. 2, article 14, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. J. R. Arron and Y. Choi, “Bone versus immune system,” Nature, vol. 408, no. 6812, pp. 535–536, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Kotake, N. Udagawa, M. Hakoda et al., “Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients,” Arthritis & Rheumatism, vol. 44, pp. 1003–1012, 2001. View at Google Scholar
  5. I. Roato, M. Grano, G. Brunetti et al., “Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement,” FASEB Journal, vol. 19, no. 2, pp. 228–230, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Roato, G. Brunetti, E. Gorassini et al., “IL-7 up-regulates TNF-α-dependent osteoclastogenesis in patients affected by solid tumor,” PLoS ONE, vol. 1, no. 1, article e124, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Brunetti, S. Colucci, P. Pignataro et al., “T cells support osteoclastogenesis in an in vitro model derived from human periodontitis patients,” Journal of Periodontology, vol. 76, no. 10, pp. 1675–1680, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Colucci, G. Brunetti, F. P. Cantatore et al., “Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFα, and IL-7 in an in vitro model derived from human psoriatic arthritis,” Journal of Pathology, vol. 212, no. 1, pp. 47–55, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. M. F. Faienza, G. Brunetti, S. Colucci et al., “Osteoclastogenesis in children with 21-hydroxylase deficiency on long-term glucocorticoid therapy: the role of receptor activator of nuclear factor-κB ligand/osteoprotegerin imbalance,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 7, pp. 2269–2276, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Brunetti, M. F. Faienza, L. Picente et al., “High dickkopf-1 levels in sera and leukocytes from children with 21-hydroxylase deficiency on chronic glucocorticoid treatment,” American Journal of Physiology, vol. 304, pp. 546–554, 2013. View at Google Scholar
  11. A. Ventura, G. Brunetti, S. Colucci et al., “Glucocorticoid-induced osteoporosis in children with 21-hydroxylase deficiency,” BioMed Research International, vol. 2013, Article ID 250462, 8 pages, 2013. View at Publisher · View at Google Scholar
  12. P. D'Amelio, A. Grimaldi, S. Di Bella et al., “Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis,” Bone, vol. 43, no. 1, pp. 92–100, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. L. M. McNamara, “Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures,” Journal of the Royal Society Interface, vol. 7, no. 44, pp. 353–372, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. U. H. Lerner, “Bone remodeling in post-menopausal osteoporosis,” Journal of Dental Research, vol. 85, no. 7, pp. 584–595, 2006. View at Google Scholar · View at Scopus
  15. L. G. Raisz, “Pathogenesis of osteoporosis: concepts, conflicts, and prospects,” The Journal of Clinical Investigation, vol. 115, no. 12, pp. 3318–3325, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. H. M. Massey and A. M. Flanagan, “Human osteoclasts derive from CD14-positive monocytes,” British Journal of Haematology, vol. 106, no. 1, pp. 167–170, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. W. J. Boyle, W. S. Simonet, and D. L. Lacey, “Osteoclast differentiation and activation,” Nature, vol. 423, no. 6937, pp. 337–342, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. M. H. Helfrich, C. W. Thesingh, R. H. P. Mieremet, and A. S. van Iperen-van Gent, “Osteoclast generation from human fetal bone marrow in cocultures with murine fetal long bones. A model for in vitro study of human osteoclast formation and function,” Cell and Tissue Research, vol. 249, no. 1, pp. 125–136, 1987. View at Google Scholar · View at Scopus
  19. N. Takahashi, T. Akatsu, N. Udagawa et al., “Osteoblastic cells are involved in osteoclast formation,” Endocrinology, vol. 123, no. 5, pp. 2600–2602, 1988. View at Google Scholar · View at Scopus
  20. T. Inaoka, G. Bilbe, O. Ishibashi, K. I. Tezuka, M. Kumegawa, and T. Kokubo, “Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone,” Biochemical and Biophysical Research Communications, vol. 206, no. 1, pp. 89–96, 1995. View at Publisher · View at Google Scholar · View at Scopus
  21. B. F. Boyce, T. Yoneda, C. Lowe, P. Soriano, and G. R. Mundy, “Requirement of pp60(c-src) expression for osteoclasts to form ruffled borders and resorb bone in mice,” The Journal of Clinical Investigation, vol. 90, no. 4, pp. 1622–1627, 1992. View at Google Scholar · View at Scopus
  22. T. A. Hentunen, S. H. Jackson, H. Chung et al., “Characterization of immortalized osteoclast precursors developed from mice transgenic for both bcl-X(L) and simian virus 40 large T antigen,” Endocrinology, vol. 140, no. 7, pp. 2954–2961, 1999. View at Google Scholar · View at Scopus
  23. J. Clover, R. A. Dodds, and M. Gowen, “Integrin subunit expression by human osteoblasts and osteoclasts in situ and in culture,” Journal of Cell Science, vol. 103, no. 1, pp. 267–271, 1992. View at Google Scholar · View at Scopus
  24. S. L. Teitelbaum, “The osteoclast and its unique cytoskeleton,” Annals of the New York Academy of Sciences, vol. 1240, pp. 14–17, 2011. View at Google Scholar
  25. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, “Osteoporosis prevention, diagnosis, and therapy,” Journal of the American Medical Association, vol. 285, no. 6, pp. 785–795, 2001. View at Google Scholar · View at Scopus
  26. C. Britton and J. Walsh, “Paget disease of bone—an update,” Australian Family Physician, vol. 41, pp. 100–103, 2012. View at Google Scholar
  27. J. A. Kanis, Pathophysiology and Treatment of Paget’s Disease of Bone, Martin Dunitz, London, UK, 1998.
  28. G. Brunetti, F. Marzano, S. Colucci et al., “Genotype-phenotype correlation in juvenile Paget disease: role of molecular alterations of the TNFRSF11B gene,” Endocrine, vol. 42, pp. 266–271, 2012. View at Google Scholar
  29. N. B. Watts, J. P. Bilezikian, P. M. Camacho, and AACE Osteoporosis Task Force, “American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis,” Endocrine Practice, vol. 16, supplement 3, pp. 1–37, 2010. View at Google Scholar
  30. B. L. Riggs, S. Khosla, and L. J. Melton III, “Sex steroids and the construction and conservation of the adult skeleton,” Endocrine Reviews, vol. 23, no. 3, pp. 279–302, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. E. I. Mohamed, U. Tarantino, L. Promenzio, and A. De Lorenzo, “Predicting bone mineral density of postmenopausal healthy and cirrhotic Italian women using age and body mass index,” Acta Diabetologica, vol. 40, supplement 1, pp. S23–S28, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. J. A. Kanis and O. Johnell, “Requirements for DXA for the management of osteoporosis in Europe,” Osteoporosis International, vol. 16, no. 3, pp. 229–238, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. J. A. Kanis, H. Johansson, A. Oden et al., “A family history of fracture and fracture risk: a meta-analysis,” Bone, vol. 35, no. 5, pp. 1029–1037, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. B. Shea, G. Wells, A. Cranney et al., “WITHDRAWN: calcium supplementation on bone loss in postmenopausal women,” Cochrane Database of Systematic Reviews, no. 3, Article ID CD004526, 2007. View at Google Scholar · View at Scopus
  35. L. Tussing and K. Chapman-Novakofski, “Osteoporosis prevention education: behavior theories and calcium intake,” Journal of the American Dietetic Association, vol. 105, no. 1, pp. 92–97, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Prentice, “Diet, nutrition and the prevention of osteoporosis,” Public Health Nutrition, vol. 7, no. 1, pp. 227–243, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. J. D. Knoke and E. Barrett-Connor, “Weight loss: a determinant of hip bone loss in older men and women: The Rancho Bernardo Study,” American Journal of Epidemiology, vol. 158, no. 12, pp. 1132–1138, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. D. L. Broussard and J. H. Magnus, “Risk assessment and screening for low bone mineral density in a multi-ethnic population of women and men: does one approach fit all?” Osteoporosis International, vol. 15, no. 5, pp. 349–360, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. X. Liu, T. Kohyama, T. Kobayashi et al., “Cigarette smoke extract inhibits chemotaxis and collagen gel contraction mediated by human bone marrow osteoprogenitor cells and osteoblast-like cells,” Osteoporosis International, vol. 14, no. 3, pp. 235–242, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. L. L. Lee, J. S. C. Lee, S. D. Waldman, R. F. Casper, and M. D. Grynpas, “Polycyclic aromatic hydrocarbons present in cigarette smoke cause bone loss in an ovariectomized rat model,” Bone, vol. 30, no. 6, pp. 917–923, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. M. A. Ford, M. A. Bass, L. W. Turner, A. Mauromoustakos, and B. S. Graves, “Past and recent physical activity and bone mineral density in college-aged women,” Journal of Strength and Conditioning Research, vol. 18, no. 3, pp. 405–409, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. T. M. Asikainen, K. Kukkonen-Harjula, and S. Miilunpalo, “Exercise for health for early postmenopausal women: a systematic review of randomised controlled trials,” Sports Medicine, vol. 34, no. 11, pp. 753–778, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. M. J. Kim, M. S. Shim, M. K. Kim et al., “Effect of chronic alcohol ingestion on bone mineral density in males without liver cirrhosis,” The Korean Journal of Internal Medicine, vol. 18, no. 3, pp. 174–180, 2003. View at Google Scholar · View at Scopus
  44. M. J. Oursler, P. Osdoby, J. Pyfferoen, B. L. Riggs, and T. C. Spelsberg, “Avian osteoclasts as estrogen target cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 15, pp. 6613–6617, 1991. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Srivastava, G. Toraldo, M. N. Weitzmann, S. Cenci, F. P. Ross, and R. Pacifici, “Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation,” The Journal of Biological Chemistry, vol. 276, no. 12, pp. 8836–8840, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. L. J. Robinson, B. B. Yaroslavskiy, R. D. Griswold et al., “Estrogen inhibits RANKL-stimulated osteoclastic differentiation of human monocytes through estrogen and RANKL-regulated interaction of estrogen receptor-α with BCAR1 and Traf6,” Experimental Cell Research, vol. 315, no. 7, pp. 1287–1301, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Eghbali-Fatourechi, S. Khosla, A. Sanyal, W. J. Boyle, D. L. Lacey, and B. L. Riggs, “Role of RANK ligand in mediating increased bone resorption in early postmenopausal women,” The Journal of Clinical Investigation, vol. 111, no. 8, pp. 1221–1230, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. L. C. Hofbauer, S. Khosla, C. R. Dunstan, D. L. Lacey, T. C. Spelsberg, and B. L. Riggs, “Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells,” Endocrinology, vol. 140, no. 9, pp. 4367–4370, 1999. View at Google Scholar · View at Scopus
  49. S. C. Manolagas and R. L. Jilka, “Mechanisms of disease: bone marrow, cytokines, and bone remodeling—emerging insights into the pathophysiology of osteoporosis,” The New England Journal of Medicine, vol. 332, no. 5, pp. 305–311, 1995. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Tanaka, N. Takahashi, N. Udagawa et al., “Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors,” The Journal of Clinical Investigation, vol. 91, no. 1, pp. 257–263, 1993. View at Google Scholar · View at Scopus
  51. R. B. Kimble, J. L. Vannice, D. C. Bloedow et al., “Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats,” The Journal of Clinical Investigation, vol. 93, no. 5, pp. 1959–1967, 1994. View at Google Scholar · View at Scopus
  52. P. Ammann, R. Rizzoli, J. P. Bonjour et al., “Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency,” The Journal of Clinical Investigation, vol. 99, no. 7, pp. 1699–1703, 1997. View at Google Scholar · View at Scopus
  53. R. B. Kimble, S. Srivastava, F. P. Ross, A. Matayoshi, and R. Pacifici, “Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1-and tumor necrosis factor- mediated stimulation of macrophage colony-stimulating factor production,” The Journal of Biological Chemistry, vol. 271, no. 46, pp. 28890–28897, 1996. View at Publisher · View at Google Scholar · View at Scopus
  54. V. Breuil, M. Ticchioni, J. Testa et al., “Immune changes in post-menopausal osteoporosis: The Immunos Study,” Osteoporosis International, vol. 21, no. 5, pp. 805–814, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Kousteni, T. Bellido, L. I. Plotkin et al., “Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity,” Cell, vol. 104, no. 5, pp. 719–730, 2001. View at Google Scholar · View at Scopus
  56. C. J. Rosen, “Pathogenesis of osteoporosis,” Baillière's Best Practice & Research, vol. 14, pp. 181–193, 2000. View at Google Scholar
  57. R. L. Jilka, G. Passeri, G. Girasole et al., “Estrogen loss upregulates hematopoiesis in the mouse: a mediating role of IL-6,” Experimental Hematology, vol. 23, no. 6, pp. 500–506, 1995. View at Google Scholar · View at Scopus
  58. R. L. Jilka, G. Hangoc, G. Girasole et al., “Increased osteoclast development after estrogen loss: mediation by interleukin-6,” Science, vol. 257, no. 5066, pp. 88–91, 1992. View at Google Scholar · View at Scopus
  59. G. B. Di Gregorio, M. Yamamoto, A. A. Ali et al., “Attenuation of the self-renewal of transit-amplifying osteoblast progenitors in the murine bone marrow by 17β-estradiol,” The Journal of Clinical Investigation, vol. 107, no. 7, pp. 803–812, 2001. View at Google Scholar · View at Scopus
  60. R. L. Jilka, K. Takahashi, M. Munshi, D. C. Williams, P. K. Roberson, and S. C. Manolagas, “Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow evidence for autonomy from factors released during bone resorption,” The Journal of Clinical Investigation, vol. 101, no. 9, pp. 1942–1950, 1998. View at Google Scholar · View at Scopus
  61. S. Kousteni, L. Han, J. R. Chen et al., “Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids,” The Journal of Clinical Investigation, vol. 111, no. 11, pp. 1651–1664, 2003. View at Google Scholar · View at Scopus
  62. S. Bord, S. Beavan, D. Ireland, A. Horner, and J. E. Compston, “Mechanisms by which high-dose estrogen therapy produces anabolic skeletal effects in postmenopausal women: role of locally produced growth factors,” Bone, vol. 29, no. 3, pp. 216–222, 2001. View at Publisher · View at Google Scholar · View at Scopus
  63. M. N. Weitzmann and R. Pacifici, “T cells: unexpected players in the bone loss induced by estrogen deficiency and in basal bone homeostasis,” Annals of the New York Academy of Sciences, vol. 1116, pp. 360–375, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. R. H. Straub, “The complex role of estrogens in inflammation,” Endocrine Reviews, vol. 28, no. 5, pp. 521–574, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Onal, J. Xiong, X. Chen et al., “Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss,” The Journal of Biological Chemistry, vol. 287, pp. 29851–29860, 2012. View at Google Scholar
  66. F. S. Mirza, I. D. Padhi, L. G. Raisz, and J. A. Lorenzo, “Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 4, pp. 1991–1997, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. B. J. Kim, S. J. Bae, S. Y. Lee et al., “TNF-αmediates the stimulation of sclerostin expression in an estrogen-deficient condition,” Biochemical and Biophysical Research Communications, vol. 424, pp. 170–175, 2012. View at Google Scholar
  68. A. M. Tyagi, K. Srivastava, M. N. Mansoori, R. Trivedi, N. Chattopadhyay, and D. Singh, “Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis,” PLoS One, vol. 7, no. 9, Article ID e44552, 2012. View at Google Scholar
  69. B. F. Boyce and L. Xing, “Bruton and Tec: new links in osteoimmunology,” Cell Metabolism, vol. 7, no. 4, pp. 283–285, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. H. Takayanagi, K. Sato, A. Takaoka, and T. Taniguchi, “Interplay between interferon and other cytokine systems in bone metabolism,” Immunological Reviews, vol. 208, pp. 181–193, 2005. View at Google Scholar · View at Scopus
  71. C. M. Brandão, G. P. Machado, and A. Acurcio Fde, “Pharmacoeconomic analysis of strategies to treat postmenopausal osteoporosis: a systematic review,” Revista Brasileira de Reumatologia, vol. 52, pp. 924–937, 2012. View at Google Scholar
  72. C. MacLean, S. Newberry, M. Maglione et al., “Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis,” Annals of Internal Medicine, vol. 148, no. 3, pp. 197–213, 2008. View at Google Scholar · View at Scopus
  73. A. Papaioannou, S. Morin, A. M. Cheung et al., “2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary,” Canadian Medical Association Journal, vol. 182, no. 17, pp. 1864–1873, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. C. J. Rosen and J. P. Bilezikian, “Clinical review 123: hot topic—anabolic therapy for osteoporosis,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 3, pp. 957–964, 2001. View at Publisher · View at Google Scholar · View at Scopus
  75. J. M. Belavic, “Denosumab, (Prolia): a new option in the treatment of osteoporosis,” Nurse Practitioner, vol. 36, pp. 11–12, 2011. View at Google Scholar
  76. M. J. Favus, “Bisphosphonates for osteoporosis,” The New England Journal of Medicine, vol. 363, no. 21, pp. 2027–2035, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. N. B. Watts and D. L. Diab, “Long-term use of bisphosphonates in osteoporosis,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 4, pp. 1555–1565, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. P. D. Miller, “A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis,” Therapeutic Advances in Musculoskeletal Disease, vol. 3, pp. 271–282, 2011. View at Google Scholar
  79. M. D. Moen and S. J. Keam, “Denosumab: a review of its use in the treatment of postmenopausal osteoporosis,” Drugs and Aging, vol. 28, no. 1, pp. 63–82, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. R. Baron, S. Ferrari, and R. G. G. Russell, “Denosumab and bisphosphonates: different mechanisms of action and effects,” Bone, vol. 48, no. 4, pp. 677–692, 2011. View at Publisher · View at Google Scholar · View at Scopus